EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Type II tyrosinemia caused by mutations at the c.843_844 inv p.(Trp282Gly) variant locus

Fei Tong, Meirong Peng, Lingzhang Meng, Jiajia Shen, Lin Huang, Weifang Huang, Weitong Huang, Jian Song

Frontiers in Genetics · 12.03.2026 · 17

DOI: 10.3389/fgene.2026.1753440 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Genetics, online erschienen am 12.03.2026. Verfasst von Fei Tong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Nanning Maternity and Child Health Hospital, Nanning, Guangxi, China. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify the genetic etiology in a neonate with persistent hypertyrosinemia and characterize the functional impact of a novel TAT gene variant, c.843_844inv.

Methods

A neonate suspected of having tyrosinemia type II following newborn screening by tandem mass spectrometry was recruited, along with family members. Whole-exome sequencing (WES) was performed to identify causative variants. To validate the pathogenicity of the identified novel locus, wild-type and mutant TAT expression vectors were constructed. These vectors were transfected into 293T cells to assess mRNA and protein expression levels in vitro . Structural modeling was also employed to predict the impact of the variant on protein stability.

Results

The proband exhibited persistently elevated blood tyrosine levels (>600 μmol/L) on repeated screenings. Genetic analysis revealed compound heterozygous variants in the TAT gene: a known pathogenic splice-site variant, c.1125 + 1G>T (maternal), and a novel variant, c.843_844inv (p. (Trp282Gly)) (paternal). The proband’s healthy sister carried only the c.843_844inv variant. In vitro functional assays demonstrated that while TAT mRNA levels were unaffected, the p. (Trp282Gly) mutation significantly reduced TAT protein expression to approximately 20.7% of wild-type levels. Structural modeling suggested that the p. (Trp282Gly) substitution disrupts critical hydrogen bonds in the enzyme’s core region.

Conclusion

A novel pathogenic variant, c.843_844inv (p. (Trp282Gly)), was identified in the TAT gene, which, in combination with c.1125 + 1G>T, causes tyrosinemia type II. Functional studies confirmed that this novel variant leads to a significant reduction in TAT protein levels. These findings expand the mutational spectrum of TAT and provide a basis for clinical diagnosis and genetic counseling.

Schlagwörter

Stichwörter der Autor:innen

TAT genec.1125 + 1G>Tc.843_844invchildrentyrosinemia type II

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Nanning Maternity and Child Health Hospital, Nanning, Guangxi, China.
  • Children's Health Department, Nanning Maternity and Child Health Hospital, Nanning, Guangxi, China.
  • Research Laboratory, Nanning Maternity and Child Health Hospital, Nanning, Guangxi, China.
  • Institute of Cardiovascular Sciences, Guangxi Academy of Medical Sciences, & The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Zitieren

APA

Tong, F., Peng, M., Meng, L., Shen, J., Huang, L., Huang, W., Huang, W., & Song, J. (2026). Case Report: Type II tyrosinemia caused by mutations at the c.843_844 inv p.(Trp282Gly) variant locus. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.1753440

Vancouver

Tong F, Peng M, Meng L, Shen J, Huang L, Huang W, et al. Case Report: Type II tyrosinemia caused by mutations at the c.843_844 inv p.(Trp282Gly) variant locus. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.1753440

BibTeX
@article{Tong2026,
  author = {Tong, Fei and Peng, Meirong and Meng, Lingzhang and Shen, Jiajia and Huang, Lin and Huang, Weifang and Huang, Weitong and Song, Jian},
  title = {Case Report: Type II tyrosinemia caused by mutations at the c.843_844 inv p.(Trp282Gly) variant locus},
  journal = {Frontiers in Genetics},
  year = {2026},
  volume = {17},
  doi = {10.3389/fgene.2026.1753440}
}
Kostenlos starten →